AstraZeneca Plc $AZN has advanced its position in the oncology sector with recent clinical trial results for its experimental breast cancer pill, camizestrant. This investigational agent, administered in combination with established cancer drugs, delivered a significant extension in progression-free survival (PFS) among women with certain breast tumor types. According to the latest data, the camizestrant regimen achieved a median of 16 months without disease progression, compared to just 9.2 months for existing standard treatments.